- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04348019
Effects of a Daily Time-Restricted Feeding Protocol on Diet Quality
November 30, 2021 updated by: Carol Johnston, Arizona State University
Mealtime Matters: An 8-wk Randomized-Controlled Trial to Examine the Effects of a Daily Time-Restricted Feeding Protocol on Diet Quality
As a result of unhealthful lifestyle practices including nighttime ingestion and excess energy-dense food and beverage intake, college students are presenting with metabolic abnormalities and excess weight gain that increases their risk for chronic health conditions including cardiovascular diseases and type 2 diabetes.
Research has shown that prolonging nightly fasting intervals can result in health improvements in both animal models and human subjects.
Time-restricted feeding (TRF), a form of intermittent fasting may offer an exciting, non-pharmacologic approach to improve cardiometabolic health in this population by restricting food intake to feeding windows that align with circadian biology.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This 8-wk randomized-controlled, parallel arm trial will examine the effects of a daily 18 h fast (TRF protocol) compared to a daily 8-h (CON protocol) on (1) diet quality, (2) cardiometabolic health, and (3) anthropometry in college students enrolled at ASU.
Institutional Review Board (IRB) approval will be granted prior to recruitment and commencement of trial activities.
Participants will be stratified by age, waist circumference, gender, and METS (activity score) and randomly assigned to one of two study arms: intervention and control.
[Women will begin the trial within 5 days of menses.]
Participants in the intervention arm of the study will consume food and beverages of their choice within one hour of waking and the feeding window will extend 6 hours.
Beyond these hours, participants will observe a prolonged fast (i.e., an 18-h overnight fast).
Participants in the control arm of the study will fast each night for 8 hours.
During fasting hours, participants will only be permitted to consume non-caloric beverages (preferably water only but unsweetened and non-caloric coffee, tea, etc. will be permitted).
Participants will adhere to their daily protocol for 8 weeks.
Participants will not receive diet instruction other than 'to fast' and are told to maintain their typical physical activity patterns for the duration of the trial.
Participants will choose one 'cheat-day' per week where they are excused from the fasting protocols; this day of the week will be consistent throughout the 8-week trial.
Diet quality will be measured by the REAP-S questionnaire, 24-h recalls will be obtained by a registered dietitian via a three-step multiple-pass interview method, a registered nurse or radiology technician will obtain fasting blood draws for biomarkers, and trained research personnel will obtain measures of anthropometry.
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Arizona Biomedical Collaborative
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy (no unresolved medical condition)
- non-smoking (includes vaping)
- normal to under-active (< 420 minutes of activity/week; not training for or competing in sports events)
- college students (≥18 years old)
- free of acute illnesses or diagnosed chronic diseases (by self-report)
- waist circumference ≥ 80 cm for women, and ≥ 94 cm for men. Participants will not be excluded based on race/ethnicity or socioeconomic status.
Exclusion Criteria:
- participants who regularly fast for >12 hours/d or adhere to a fasting regimen (i.e., alternate day fasting, Ramadan-style fasting, 5:2 fasting) at the time of screening or within the past six months
- those with weight loss attempt(s) or weight change (≥ 5 lbs.) within the past six months (including pregnancy)
- those with a history of weight cycling (repeated weight loss and weight gain over time)
- those who currently work night-shifts (i.e., midnight to 6AM), and those unwilling to adhere to the protocol will be excluded from the trial
- pregnant or lactating women, and women not on prescription contraceptives (i.e., birth control pills, IUDs, and patches) (however, if a female applicant states her menstrual cycle is regular, the need to be on prescription contraceptives will be waived)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Time restricted feeding
Participants in the intervention arm of the study will consume food and beverages of their choice within one hour of waking and the feeding window will extend 6 hours.
Beyond these hours, participants will observe a prolonged fast (i.e., an 18-h overnight fast).
|
Fasting was defined as no foods or caloric beverages.
|
Placebo Comparator: Control
Participants in the control arm of the study will fast each night for 8 hours.
|
Fasting was defined as no foods or caloric beverages.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diet quality
Time Frame: Change from Baseline at week 8
|
A REAP-S questionnaire will be completed for the previous week's intake during Trial Visits 1-3.
The REAP-S questionnaire is a 16-item validated measure of diet quality whereby participants respond to questions that estimate the intake of fruits and vegetables, fiber, sugar, milk, fat, and dietary cholesterol.
Responses of 'usually/often' will receive 1 point, 'sometimes' will receive 2 points, and 'rarely/never or does not apply to me' will receive 3 points.
Per the REAP-S protocol, responses will be tabulated, and higher scores will indicate better diet quality.
|
Change from Baseline at week 8
|
Blood pressure
Time Frame: Change from Baseline at week 8
|
Both systolic and diastolic blood pressure will be obtained prior to blood draw.
Participants will be instructed to sit quietly with their feet planted flat on the floor.
After a 10-minute rest period, a non-invasive Omron auto cuff blood pressure monitor equipped with IntelliSense technology, which allows the machine to inflate and deflate at optimum levels depending on arm size, will be utilized to obtain blood pressure in mm Hg.
|
Change from Baseline at week 8
|
Blood lipids
Time Frame: Change from Baseline at week 8
|
. LDL and HDL cholesterol will be measured using a commercially available diagnostic test kit on a bench-top, fully automated, clinical chemistry analyzer (Randox Laboratories Ltd, Crumlin, UK), and results will be expressed in milligrams per deciliter (mg/dL).
Triglycerides will be measured using a commercially available diagnostic test kit on a bench-top, fully automated, clinical chemistry analyzer (Randox Laboratories Ltd, Crumlin, UK), and results will be expressed in milligrams per deciliter (mg/dL).
|
Change from Baseline at week 8
|
Waist circumference
Time Frame: Change from Baseline at week 8
|
Waist circumference will be obtained to the nearest 5 cm using a research-grade ergonomic measuring tape placed horizontally around participants' natural waist (i.e., narrowest circumference above the umbilicus).
Waist circumference will be measured twice and averaged unless the difference between the first and second measurement is above 5 cm.
In that event, a third measurement will be obtained, and the mean of the nearest two circumferences will be recorded.
|
Change from Baseline at week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 11, 2019
Primary Completion (Actual)
April 30, 2020
Study Completion (Actual)
December 30, 2020
Study Registration Dates
First Submitted
April 13, 2020
First Submitted That Met QC Criteria
April 13, 2020
First Posted (Actual)
April 15, 2020
Study Record Updates
Last Update Posted (Actual)
December 2, 2021
Last Update Submitted That Met QC Criteria
November 30, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRF-DQ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemias
-
IlDong Pharmaceutical Co LtdCompletedMixed DyslipidemiasKorea, Republic of
-
Orient Pharma Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed DyslipidemiasTaiwan, Australia, New Zealand
-
University of PaviaFoundation IRCCS San Matteo HospitalRecruiting
-
Çankırı Karatekin UniversityHacettepe UniversityRecruiting
-
Daewoong Pharmaceutical Co. LTD.RecruitingDyslipidemiasKorea, Republic of
-
AstraZenecaParexelRecruitingDyslipidemiaUnited States, United Kingdom
-
Jiangxi University of Traditional Chinese MedicineNot yet recruiting
-
Mackay Memorial HospitalAmgenRecruiting
-
EMSRecruiting
-
Daiichi SankyoDaiichi Sankyo Korea Co., Ltd.Active, not recruiting
Clinical Trials on Fasting
-
Kasr El Aini HospitalCompleted
-
Charite University, Berlin, GermanyKarl and Veronica Carstens FoundationTerminatedFertility Issues | Fertility Disorders | IVF | Sub Fertility, Female | Sub-fertilityGermany
-
Cairo UniversityWithdrawnPolycystic Ovary Syndrome | InfertilityEgypt
-
Shiraz University of Medical SciencesCompletedCoronary Artery DiseaseIran, Islamic Republic of
-
Charite University, Berlin, GermanyCompletedCancer | Fasting | NeoplasiaGermany
-
HealthPartners InstituteCompletedDiabetes Mellitus | Hyperlipidemia | Normal Glucose MetabolismUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNot yet recruitingPancreatitis | Pancreatitis, Chronic | Pancreatitis, Acute | Pancreas Disease | Acute Recurrent PancreatitisUnited States
-
Nottingham Trent UniversityLoughborough UniversityCompleted
-
Universidade de Passo FundoFederal University of Rio Grande do SulCompleted
-
Mahidol UniversityHealth Systems Research InstituteEnrolling by invitationWeight Loss | Obese | Intermittent Fasting | Behavioral Economic | HOMA-IRThailand